36.01  0 (0%)		01-10 16:00
Open: 36 High: 36.02 Volume: 138,127		Pre. Close: 36.01 Low: 35.99 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	42.15	1-year :	49.23
Resists	First :	36.09	Second :	42.15
Pivot price	35.97
Supports	First :	35.87	Second :	35.74
MAs	MA(5) :	36	MA(20) :	35.93
	MA(100) :	23.37	MA(250) :	19.97
MACD	MACD :	1.1	Signal :	1.5
%K %D	K(14,3) :	74.9	D(3) :	72.7
RSI	RSI(14): 86.3
52-week	High :	36.09	Low :	11.56

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ IMGO ] has closed below upper band by 21.0%. Bollinger Bands are 97.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	36.06 - 36.24	36.24 - 36.39
Low:	35.58 - 35.78	35.78 - 35.94
Close:	35.72 - 36.03	36.03 - 36.28

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Mon, 12 Dec 2022
Merck Officially Commences $1.36B Imago Buyout - BioSpace

Mon, 21 Nov 2022
These 10 Stocks are Skyrocketing Today - Yahoo Finance

Mon, 21 Nov 2022
Why Merck (MRK) Is Buying Imago BioSciences (IMGO) For $1.35 Billion - Pulse 2.0

Mon, 21 Nov 2022
Cancer-Focused Imago BioSciences Shares Soar After Merck Deal - Yahoo Finance

Mon, 21 Nov 2022
Merck to Acquire Imago BioSciences, Inc. - Business Wire

Mon, 21 Nov 2022
Merck to buy Imago for $1.35 bln to broaden portfolio of blood disorder drugs - Reuters

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	34 (M)
Shares Float	16 (M)
Held by Insiders	3.5 (%)
Held by Institutions	99.1 (%)
Shares Short	1,000 (K)
Shares Short P.Month	3,430 (K)

EPS	-2.17
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	5.11
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-18.6 %
Return on Equity (ttm)	-30.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.86
Qtrly Earnings Growth	0 %
Operating Cash Flow	-52 (M)
Levered Free Cash Flow	-28 (M)

PE Ratio	-16.68
PEG Ratio	0
Price to Book value	7.04
Price to Sales	0
Price to Cash Flow	-23.31

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.